JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME Activity
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weber, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weber, W. A.
Journal of Nuclear Medicine Vol. 46 No. 6 983-995
© 2005 by Society of Nuclear Medicine


Continuing Education

Use of PET for Monitoring Cancer Therapy and for Predicting Outcome*

Wolfgang A. Weber, MD

1 Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California

PET with the glucose analog 18F-FDG is increasingly used to monitor tumor response in patients undergoing chemotherapy and chemoradiotherapy. Numerous studies have shown that 18F-FDG PET is an accurate test for differentiating residual viable tumor tissue from therapy-induced fibrosis. Furthermore, quantitative assessment of therapy-induced changes in tumor 18F-FDG uptake may allow the prediction of tumor response and patient outcome very early in the course of therapy. Treatment may be adjusted according to the chemosensitivity and radiosensitivity of the tumor tissue in an individual patient. Thus, 18F-FDG PET has an enormous potential to reduce the side effects and costs of ineffective therapy. This review focuses on the practical aspects of 18F-FDG PET for treatment monitoring and on how to perform a quantitative assessment of tumor 18F-FDG uptake in clinical studies.

Key Words: FDG • PET • treatment monitoring • cancer




This article has been cited by other articles:


Home page
JNMHome page
R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
W. A. Weber
Assessing Tumor Response to Therapy
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
R. Boellaard
Standards for PET Image Acquisition and Quantitative Data Analysis
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 11S - 20S.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. K. Shankar, A. Van den Abbeele, J. Yap, R. Benjamin, S. Scheutze, and T.J. FitzGerald
Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology
Clin. Cancer Res., March 15, 2009; 15(6): 1891 - 1897.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
W. A. Weber
The Use of Positron Emission Tomography versus Computerized Tomography Scans in the Assessment of Response to Therapy
ASCO Educational Book, January 1, 2009; 2009(1): 474 - 478.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
C. Nahmias and L. M. Wahl
Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors
J. Nucl. Med., November 1, 2008; 49(11): 1804 - 1808.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
H.-Y. Lee, Z. Li, K. Chen, A. R. Hsu, C. Xu, J. Xie, S. Sun, and X. Chen
PET/MRI Dual-Modality Tumor Imaging Using Arginine-Glycine-Aspartic (RGD)-Conjugated Radiolabeled Iron Oxide Nanoparticles
J. Nucl. Med., August 1, 2008; 49(8): 1371 - 1379.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. F. Shields, J. M. Lawhorn-Crews, D. A. Briston, S. Zalzala, S. Gadgeel, K. A. Douglas, T. J. Mangner, L. K. Heilbrun, and O. Muzik
Analysis and Reproducibility of 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer
Clin. Cancer Res., July 15, 2008; 14(14): 4463 - 4468.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
D. W. Townsend
Dual-Modality Imaging: Combining Anatomy and Function
J. Nucl. Med., June 1, 2008; 49(6): 938 - 955.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
D. L. Schwartz, H. A. Macapinlac, and R. S. Weber
FDG-PET Staging of Head and Neck Cancer--Can Improved Imaging Lead to Improved Treatment?
J Natl Cancer Inst, May 21, 2008; 100(10): 688 - 689.
[Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
H. Lau, T. Phan, J. MacKinnon, and T. W. Matthews
Absence of Planned Neck Dissection for the N2-N3 Neck After Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Arch Otolaryngol Head Neck Surg, March 1, 2008; 134(3): 257 - 261.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. Evilevitch, W. A. Weber, W. D. Tap, M. Allen-Auerbach, K. Chow, S. D. Nelson, F. R. Eilber, J. J. Eckardt, R. M. Elashoff, M. E. Phelps, et al.
Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue Sarcomas
Clin. Cancer Res., February 1, 2008; 14(3): 715 - 720.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens
Application of PET/CT in the Development of Novel Anticancer Drugs
Oncologist, January 1, 2008; 13(1): 25 - 38.
[Abstract] [Full Text] [PDF]


Home page
J. Nucl. Med. Technol.Home page
D. C. Vines, H. Keller, J. D.P. Hoisak, and S. L. Breen
Quantitative PET Comparing Gated with Nongated Acquisitions Using a NEMA Phantom with Respiratory-Simulated Motion
J. Nucl. Med. Technol., December 1, 2007; 35(4): 246 - 251.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. Tatsumi, J. H. Miller, and R. L. Wahl
18F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies
J. Nucl. Med., December 1, 2007; 48(12): 1923 - 1931.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir
Molecular Imaging Techniques in Body Imaging
Radiology, November 1, 2007; 245(2): 333 - 356.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
W. A. Weber
18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative?
J. Nucl. Med., October 1, 2007; 48(10): 1580 - 1582.
[Full Text] [PDF]


Home page
RadiologyHome page
G. P. Krestin, J. C. Miller, S. J. Golding, G. G. Frija, G. M. Glazer, H. G. Ringertz, and J. H. Thrall
Reinventing Radiology in a Digital and Molecular Age: Summary of Proceedings of the Sixth Biannual Symposium of the International Society for Strategic Studies in Radiology (IS3R), August 25 27, 2005
Radiology, September 1, 2007; 244(3): 633 - 638.
[Full Text] [PDF]


Home page
JCOHome page
D. P. Kelsen, K. A. Winter, L. L. Gunderson, J. Mortimer, N. C. Estes, D. G. Haller, J. A. Ajani, W. Kocha, B. D. Minsky, J. A. Roth, et al.
Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer
J. Clin. Oncol., August 20, 2007; 25(24): 3719 - 3725.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
R. L. Ehman, W. R. Hendee, M. J. Welch, N. R. Dunnick, L. B. Bresolin, R. L. Arenson, S. Baum, H. Hricak, and J. H. Thrall
Blueprint for Imaging in Biomedical Research
Radiology, July 1, 2007; 244(1): 12 - 27.
[Full Text] [PDF]


Home page
JNMHome page
M. Soret, S. L. Bacharach, and I. Buvat
Partial-Volume Effect in PET Tumor Imaging
J. Nucl. Med., June 1, 2007; 48(6): 932 - 945.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
B.-K. Teo, Y. Seo, S. L. Bacharach, J. A. Carrasquillo, S. K. Libutti, H. Shukla, B. H. Hasegawa, R. A. Hawkins, and B. L. Franc
Partial-Volume Correction in PET: Validation of an Iterative Postreconstruction Method with Phantom and Patient Data
J. Nucl. Med., May 1, 2007; 48(5): 802 - 810.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. L. Ceresoli, A. Chiti, P. A. Zucali, M. Rodari, R. F. Lutman, S. Salamina, M. Incarbone, M. Alloisio, and A. Santoro
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
J. Clin. Oncol., October 1, 2006; 24(28): 4587 - 4593.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Su, C. Bodenstein, R. A. Dumont, Y. Seimbille, S. Dubinett, M. E. Phelps, H. Herschman, J. Czernin, and W. Weber
Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors.
Clin. Cancer Res., October 1, 2006; 12(19): 5659 - 5667.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
Y. S. Jhanwar and D. J. Straus
The Role of PET in Lymphoma
J. Nucl. Med., August 1, 2006; 47(8): 1326 - 1334.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
H.-E. Wang, H.-M. Yu, R.-S. Liu, M. Lin, J. G. Gelovani, J.-J. Hwang, H.-J. Wei, and W.-P. Deng
Molecular Imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for Monitoring Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Prodrug Activation Gene Therapy of Cancer
J. Nucl. Med., July 1, 2006; 47(7): 1161 - 1171.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
D. Delbeke, R. E. Coleman, M. J. Guiberteau, M. L. Brown, H. D. Royal, B. A. Siegel, D. W. Townsend, L. L. Berland, J. A. Parker, K. Hubner, et al.
Procedure Guideline for Tumor Imaging with 18F-FDG PET/CT 1.0
J. Nucl. Med., May 1, 2006; 47(5): 885 - 895.
[Full Text] [PDF]


Home page
JNMHome page
T. Bunyaviroch and R. E. Coleman
PET Evaluation of Lung Cancer
J. Nucl. Med., March 1, 2006; 47(3): 451 - 469.
[Full Text] [PDF]


Home page
JNMHome page
V. Kalff, C. Duong, E. G. Drummond, J. P. Matthews, and R. J. Hicks
Findings on 18F-FDG PET Scans After Neoadjuvant Chemoradiation Provides Prognostic Stratification in Patients with Locally Advanced Rectal Carcinoma Subsequently Treated by Radical Surgery
J. Nucl. Med., January 1, 2006; 47(1): 14 - 22.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.